Category: Market News

Avacta (LSE:AVCT) has dosed the first patient in its Phase 1 FOCUS-01 clinical trial evaluating FAP-Exd (AVA6103), a Gen Two pre|CISION-based exatecan peptide drug conjugate designed to treat selected advanced solid tumours. The trial is being conducted at three specialist oncology centres in the United States.

The study follows a recent £10 million fundraising that extended the company’s cash runway into early 2027. FOCUS-01 is expected to enrol around 144 patients and will employ AI-assisted tumour selection together with a Bayesian dose-escalation framework. The trial aims to deliver initial safety, pharmacokinetic and early efficacy data later this year, marking an important milestone in the development of Avacta’s targeted oncology pipeline and further validation of its tumour-activated drug platform.

The trial will focus on cancers including pancreatic, cervical and vulvar, gastric and gastroesophageal junction, and small cell lung cancer. Patient selection is supported by gene-expression analysis from Tempus AI, which is being used to identify tumours where fibroblast activation protein (FAP) expression aligns with potential sensitivity to topoisomerase I inhibition.

The study will also test two different dosing schedules while evaluating a sustained-release mechanism designed to increase drug concentration within tumours while limiting exposure to healthy tissue. If successful, AVA6103 could expand the clinical and commercial potential of Avacta’s pre|CISION platform beyond its lead candidate AVA6000 and strengthen the company’s position in the emerging class of exatecan-based targeted therapies.

Despite the clinical progress, Avacta’s outlook remains constrained by financial pressures. The company continues to report losses and lacks significant commercial partnerships, which increases funding risk as its pipeline advances. Technical indicators for the stock also remain weak, and valuation metrics are challenged by negative earnings and the absence of dividend income.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biotechnology and life sciences company focused on developing innovative cancer treatments. Its proprietary pre|CISION platform is designed to activate potent peptide drug conjugates within the tumour microenvironment using fibroblast activation protein (FAP). This approach aims to deliver highly effective therapeutic payloads directly to solid tumours while minimising systemic toxicity and improving dosing flexibility for patients.

Quantum Data Energy PLC (LSE:QDE) said its wholly owned 8.1 MW Pyebridge flexible generation facility delivered strong operational results in the first quarter of 2026, producing approximately 3.3 GWh of electricity. This represented a 61% increase compared with the same period a year earlier, reflecting growing demand for flexible generation capacity as renewable energy supply remains intermittent.

Over the 12 months to March 2026, the Pyebridge site generated around 12 GWh of electricity. The asset achieved average annual revenues of roughly £285,000 per MW, with electricity sold at an average price of £126 per MWh. The facility operated for approximately 12 hours per day on average, highlighting strong utilisation levels and significant performance above prevailing wholesale power market prices.

The company also confirmed that the ongoing conflict involving Iran has not materially affected its operations. Management noted that the UK has limited gas supply exposure to the region and that electricity forward markets have adjusted to higher gas costs. According to the company, this environment resembles conditions during the Ukraine war, which previously supported strong trading conditions for gas-fired flexible generation assets.

Quantum Data Energy believes these dynamics reinforce the resilience of its business model and support its strategy of scaling its portfolio toward an initial target of 300 MW of flexible generation capacity. The company is also positioning its assets to support rising electricity demand from AI data centres and other power-intensive infrastructure.

Despite strong operational performance at Pyebridge, the company’s outlook remains constrained by underlying financial challenges. Quantum Data Energy continues to report operating losses and negative operating and free cash flow, while leverage has increased. Technical indicators also suggest a sustained downward trend in the share price, with only mild signs of oversold conditions. Valuation offers limited support, as the company’s losses make traditional P/E metrics less meaningful and no dividend yield is available.

More about Quantum Data Energy PLC

Quantum Data Energy PLC is a UK-based developer, owner and operator of flexible generation power assets. The company specialises in modular gas-fired generation solutions designed to provide responsive power to the UK grid and energy-intensive applications such as AI data centres. Leveraging expertise in infrastructure planning, grid connectivity and gas access, the company aims to expand its flexible generation portfolio and establish itself as a leading AI-focused energy infrastructure platform on the London Stock Exchange.

Tap Global Group PLC (LSE:TAP), the AIM-listed digital finance platform, reported first-half revenue of £1.67 million for the six months to 31 December 2025, representing a 6.9% year-on-year decline amid softer conditions in cryptocurrency markets.

Despite the slight revenue drop, the company maintained strong gross margins above 75%. However, higher operating costs led to an EBITDA loss of £0.15 million and a pre-tax loss of £0.5 million for the period. Cash balances at the end of the half-year stood at £433,000.

During the period, Tap Global continued advancing its strategy of positioning itself as a regulated bridge between traditional fiat payments and digital assets. The company integrated open banking services through tell.money and partnered with Moorwand to introduce dedicated GBP and EUR IBAN accounts alongside improved payment infrastructure.

Tap Global also relaunched its corporate customer programme, onboarding more than 25 business clients. In addition, it introduced a Bitcoin Treasury as a Service offering aimed at institutional users, which has already secured its first client. These developments form part of the company’s broader shift toward higher-margin B2B services and are intended to support more diversified and sustainable long-term growth.

More about Tap Global Group PLC

Tap Global Group PLC is a digital finance platform designed to connect traditional fiat payments with blockchain-based financial services through a single mobile application. The platform serves more than 400,000 individual and business users, providing integrated fiat accounts, payment cards and access to more than 70 cryptocurrencies across over 40 countries. The company operates within European regulatory frameworks and holds licences in Gibraltar and Bulgaria.

Hilton Food Group (LSE:HFG) reported resilient trading for 2025, supported by stable volumes across its core retail meat and fresh prepared foods operations. Revenue from continuing activities increased by nearly 12% on a constant currency basis, demonstrating steady demand despite persistent inflationary pressures across the supply chain.

Adjusted profit before tax from continuing operations declined slightly, slipping around 1% year on year, largely due to weaker performance at the Seachill seafood division. At the statutory level, exceptional costs related to regulatory matters at Foppen were offset by gains from asset disposals and a reduction in net bank debt, helping to stabilise overall financial results.

During the year, the group completed a strategic review aimed at concentrating growth and capital investment on its core meat and fresh prepared food segments. Alongside this shift, improvement programmes are being implemented at Seachill, Foppen and Dalco to enhance operational performance and broaden the company’s strategic options for these businesses.

Looking ahead, management reiterated that profit in 2026 is expected to come in below 2025 levels, reflecting continued challenges within the seafood and specialty food divisions. However, the company pointed to strong core volumes and new contract wins across continental Europe as positive indicators. Hilton Food is also investing in major capacity expansions in Canada, Saudi Arabia and Poland, which it believes will support future growth.

The group remains committed to a progressive dividend policy designed to maintain shareholder returns while supporting longer-term objectives around profit growth, improved cash conversion and stronger returns on capital.

From an investment perspective, Hilton Food’s outlook is underpinned by a relatively attractive valuation and solid financial performance, although operational headwinds and bearish technical indicators present some near-term risks. Strategic initiatives and confidence from insiders nevertheless provide a supportive longer-term outlook.

More about Hilton Food

Hilton Food Group is an international food packing and supply partner for major grocery retailers, specialising primarily in red meat and fresh prepared foods. The company operates highly automated production facilities and long-term retail partnerships across the UK, Europe and newer growth markets such as Canada and Saudi Arabia. Its strategy focuses on expanding into under-served markets while strengthening relationships with global retailers to support long-term growth.

EnSilica (LSE:ENSI) has been selected as one of three semiconductor supply chain partners in the newly established CHERI Adoption Collective, an initiative launched by PA Consulting in collaboration with the UK Department for Science, Innovation & Technology. The programme brings together major infrastructure operators—including BT, National Grid and SSE—alongside defence and industrial partners to address the UK’s estimated £27bn cyber resilience challenge.

The Collective is designed to accelerate the deployment of CHERI technology, a microchip architecture that enhances cybersecurity at the hardware level. By improving memory safety, CHERI aims to mitigate vulnerabilities that are responsible for the majority of software security flaws.

As part of the initiative, EnSilica will contribute its EnSura secure microcontroller platform, which incorporates CHERI-enabled RISC-V architecture along with support for post-quantum cryptography. Participation in the programme positions the company to capitalise on emerging opportunities in secure computing systems and critical infrastructure markets where advanced cybersecurity capabilities are increasingly required.

Despite this strategic progress, EnSilica’s financial outlook remains constrained by underlying performance challenges. The company continues to face declining revenue, ongoing operating losses and sharply deteriorating free cash flow, although its balance sheet remains relatively manageable in terms of leverage. Technical indicators provide some counterbalance, with the share price trading well above major moving averages and showing strong upward momentum, though signals suggest conditions may be approaching overextended levels. Valuation also remains pressured as the company is currently loss-making and does not offer a dividend yield.

More about EnSilica plc

EnSilica plc is a fabless semiconductor company specialising in the design of application-specific integrated circuits (ASICs), including RF, mmWave, mixed-signal and complex digital chips. The business serves sectors such as space and communications, industrial technology, automotive and healthcare, with a focus on safety, security and reliability. Its reusable intellectual property and silicon platforms enable scalable product development and long-term supply revenues. EnSilica operates design centres in the UK, India, Brazil and Hungary.

BRCK Group PLC (LSE:BRCK) has revealed it received an unsolicited, indicative and non-binding takeover proposal from Atlas Holdings LLC, which later submitted a potential all-cash offer of 65 pence per share for the company. After reviewing the proposal alongside its financial advisers, the board unanimously rejected the approach, stating that the offer significantly undervalued the business. However, the company has agreed to share limited additional information to allow Atlas the opportunity to consider submitting a higher bid.

The board reaffirmed its confidence in BRCK’s prospects as an independent listed company and advised shareholders not to take any action while discussions remain at an early stage. Under the rules of the UK Takeover Code, Atlas must by 28 April 2026 either confirm a firm intention to make an offer or announce that it does not intend to proceed. This requirement formally places the company in an offer period, increasing scrutiny from investors and industry observers regarding the group’s potential ownership and valuation.

BRCK’s broader outlook combines steady financial performance with ongoing strategic developments. The company benefits from stable revenue growth and an attractive dividend yield, which remain key strengths. Nevertheless, pressure on profitability and cash flow management continues to pose challenges, while technical indicators currently point to a weaker market trend. Recent corporate developments and strategic initiatives may provide momentum for future growth if operational improvements continue.

More about BRCK Group PLC

BRCK Group PLC is a UK-based distributor and supplier of specialist products and services to the construction sector. The company operates across bricks and building materials distribution, importing, and contracting services. Established in 1985, the group has expanded through a mix of organic growth and acquisitions and now employs more than 800 people while managing a portfolio of brands serving construction and development projects across the UK.

Shield Therapeutics (LSE:STX) has received a regulatory boost after a European Medicines Agency committee recommended extending the approved use of FeRACCRU to include adolescent patients. The positive opinion allows the iron deficiency treatment to be prescribed for individuals aged 12 and above, expanding its existing patient base.

The recommendation follows completion of the company’s agreed pediatric investigation plan and is supported by encouraging Phase 3 trial results demonstrating the efficacy and safety of ferric maltol in children. The development strengthens the drug’s pediatric profile in Europe, complementing earlier regulatory approval for similar use in the United States.

Under Shield’s European licensing agreement, Norgine holds the marketing authorisation for FeRACCRU and will be responsible for commercialising the expanded indication across the region. The regulatory milestone will trigger a €500,000 payment to Shield under the terms of the partnership.

The approval is expected to support broader adoption of ferric maltol and enhance its position in the global iron deficiency treatment market as a differentiated oral therapy. It also aligns with Shield’s strategy of leveraging regional commercial partners to expand revenues outside the United States.

From an investment perspective, the company’s outlook reflects a mix of encouraging corporate developments and financial headwinds. Recent regulatory progress and strong technical momentum in the share price offer positive signals. However, ongoing financial challenges and valuation concerns remain key risks for investors.

More about Shield Therapeutics

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on the treatment of iron deficiency and iron deficiency anaemia. Its ferric maltol product is marketed as ACCRUFeR in the United States and FeRACCRU in Europe and other international markets. The company operates through licensing partnerships with regional pharmaceutical firms, including Viatris in the U.S. and Norgine in Europe, alongside additional partners across Canada, Asia-Pacific and China. Patent protection for ferric maltol is expected to extend into the mid-2030s.

Kazera Global (LSE:KZG) reported meaningful operational progress for the six months to 31 December 2025, with its mineral sands and diamond operations in South Africa transitioning from development toward early production while the group continued strengthening its financial position.

At Whale Head Minerals, newly installed processing infrastructure has begun producing consistent heavy mineral concentrates grading around 32% TiO₂. The company is currently implementing plant upgrades and introducing additional operating shifts in an effort to increase production capacity. Management said this progress could support negotiations for higher-value offtake agreements once the long-delayed 2A Mining Right clears the existing regulatory backlog.

Within the group’s diamond operations, Deep Blue Minerals achieved its first diamond recoveries and initial sales following the commissioning of a new jig and FlowSort recovery system. Early results have been encouraging, with both grades and recovery rates exceeding expectations. In addition, a revised agreement with Alexkor has improved Kazera’s share of revenue as the project scales up production.

Elsewhere, the Aftan tantalum and lithium project remains a strategic focus. Kazera is pursuing enforcement of a multi-million-dollar arbitration award against former buyer Hebei while also engaging with potential development partners. However, discussions with counterparties have been cautious pending a decision from the Namibian Supreme Court related to the dispute. To support future development, the company has raised new equity, extended loan facilities and added technical personnel, providing additional funding and operational capacity as it prepares for its next growth stage.

Despite these operational advances, Kazera’s financial outlook remains constrained. The company reported no revenue for 2025 and continues to post significant losses alongside ongoing cash burn. Technical indicators also point to a weak share price trend, with the stock trading below key moving averages and showing a negative MACD signal. Valuation support remains limited as the negative P/E ratio reflects continued losses, and there is no dividend yield available.

More about Kazera Global plc

Kazera Global is an AIM-listed investment company focused on developing natural resource projects across southern Africa. Its portfolio includes interests in heavy mineral sands, diamonds and tantalum-lithium assets. Through subsidiaries such as Whale Head Minerals, Deep Blue Minerals and African Tantalum, the company is working to advance projects toward early-stage production and unlock value from titanium-rich mineral sands, alluvial and inland diamond deposits, and hard-rock tantalum and lithium resources.